NDA 022288 · Bausch and Lomb INC
Bepreve
Bepotastine Besilate · Ophthalmic
NovelLast checked: Nov 19, 2026Latest source record: Feb 9, 2018 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2009
Sep 8, 2009
Approved uses
1
Original approval plus efficacy supplements
Registered trials
25
7 Phase 3, 0 recruiting
FAERS reports
644
361 serious, 38 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Aug 20, 2024.
Bepotastine Besilate Ophthalmic Solution, 1.5% is a histamine H 1 receptor antagonist indicated for the treatment of itching associated with signs and symptoms of allergic conjunctivitis. Bepotastine Besilate Ophthalmic Solution is a histamine H1 receptor antagonist indicated for the treatment of itching associated with allergic conjunctivitis. ( 1 )
Mechanism: Bepotastine is a topically active, direct H1-receptor antagonist and an inhibitor of the release of histamine from mast cells.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Sep 8, 2009 Original approval · Type 1 - New Molecular Entity NovelReviewSummary ReviewPediatric Medical Review
1 products under this application
- BEPREVE · BEPOTASTINE BESILATE 1.5% · SOLUTION/DROPS, OPHTHALMIC · Prescription · TE AT
Clinical trials
Interventional ClinicalTrials.gov studies with "Bepotastine Besilate" as an intervention, any sponsor and status, largest first.
- Safety Study for Bepotastine Besilate Ophthalmic Solution in Normal VolunteersPivotal-lookingCompleted
Bausch & Lomb IncorporatedIndustry
NCT00586625 · 861 participants · Start Oct 2007 · Primary completion May 2008
Drug: Bepreve; Placebo · For: Allergic Conjunctivitis
- Bepotastine Besilate Nasal Sprays in the Treatment of Seasonal Allergic Rhinitis (SAR)Pivotal-lookingCompleted
Bausch & Lomb IncorporatedIndustry
NCT01753739 · 617 participants · Start Jan 2013 · Primary completion Feb 2013
Drug: Bepotastine besilate; Placebo · For: Seasonal Allergic Rhinitis
Sites: Irvine, California
- Bepotastine Besilate-corticosteroid Nasal Spray Combination Compared to Placebo, Bepotastine Besilate Nasal Spray, and Corticosteroid Nasal Spray in the Treatment of Patients With Seasonal Allergic RhinitisPivotal-lookingCompleted
Bausch & Lomb IncorporatedIndustry
NCT01578278 · 606 participants · Start Dec 2011 · Primary completion Aug 2012
Drug: Bepotastine besilate formulation; Fluticasone propionate and 2 more · For: Seasonal Allergic Rhinitis
Sites: Irvine, California
- Safety and Efficacy of Bepotastine Besilate Nasal Spray in the Treatment of Seasonal Allergic RhinitisPivotal-lookingCompleted
Bausch & Lomb IncorporatedIndustry
NCT01277341 · 601 participants · Start Dec 2010 · Primary completion Feb 2011
Drug: Bepotastine Besilate Nasal Spray 2% Twice a day; Bepotastine Besilate Nasal Spray 3% Twice a day and 2 more · For: Seasonal Allergic Rhinitis
Sites: Irvine, California
- A Confirmatory Study of TAU-284 in Pediatric Patients With Perennial Allergic RhinitisPivotal-lookingCompleted
Tanabe Pharma CorporationIndustry
NCT01425632 · 490 participants · Start Aug 2011 · Primary completion Dec 2011
Drug: TAU-284; TAU-284 and 1 more · For: Perennial Allergic Rhinitis
Sites: Chūbu, Japan; Hokuriku, Japan; Kanto, Japan · 5 sites in all
- The Confirmatory Study of TAU-284 in Pediatric Patients With Perennial Allergic RhinitisPivotal-lookingCompleted
Tanabe Pharma CorporationIndustry
NCT01861522 · 473 participants · Start Apr 2013 · Primary completion Dec 2013
Drug: Bepotastine besilate; Placebo · For: Perennial Allergic Rhinitis
Sites: Fukuoka, Japan; Toyama, Japan
- A Confirmatory Study of TAU-284 in Pediatric Patients With Atopic DermatitisPivotal-lookingCompleted
Tanabe Pharma CorporationIndustry
NCT01840605 · 303 participants · Start Mar 2013 · Primary completion Nov 2013
Drug: Bepotastine besilate; ketotifen fumarate · For: Dermatitis; Atopic
Sites: Hokkaido, Japan
- Safety and Efficacy of Bepotastine Besilate Ophthalmic Solution in Seasonal Allergic Conjunctivitis PatientsPivotal-lookingCompleted
Bausch & Lomb IncorporatedIndustry
NCT01174823 · 245 participants · Start Jun 2010 · Primary completion Oct 2010
Drug: bepotastine besilate ophthalmic solution; placebo comparator ophthalmic solution · For: Allergic Conjunctivitis
Sites: Irvine, California
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective45
- headache36
- nausea33
- eye irritation32
- fatigue32
- pain29
- diarrhoea28
- pruritus27
- treatment failure26
- dyspnoea25
- off label use25
- asthma24
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2005 | 2 |
| 2008 | 3 |
| 2009 | 2 |
| 2010 | 22 |
| 2011 | 46 |
| 2012 | 11 |
| 2013 | 18 |
| 2014 | 17 |
| 2015 | 45 |
| 2016 | 47 |
| 2017 | 73 |
| 2018 | 62 |
| 2019 | 76 |
| 2020 | 65 |
| 2021 | 54 |
| 2022 | 22 |
| 2023 | 25 |
| 2024 | 22 |
| 2025 | 23 |
| 2026 | 9 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Bepreve (Bepotastine Besilate)
2024 spending
$1.5M
Beneficiaries
1,193
3,553 claims
Per beneficiary
$1,257
$54.52 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $18,279,728 |
| 2021 | $18,335,829 |
| 2022 | $11,213,463 |
| 2023 | $3,010,497 |
| 2024 | $1,499,995 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Comparative Effectiveness and Safety of Second-Generation Antihistamines Treatments for Chronic Urticaria: A Network Meta-Analysis.
Tian HY, Xu C, Liu CJ, et al. · Int Arch Allergy Immunol 2026 · Network Meta-Analysis, Comparative Study
- Efficacy and Toxicity Evaluation of Bepotastine Besilate 1.5% Preservative-Free Eye Drops Vs Olopatadine Hydrochloride 0.2% Bak-Preserved Eye Drops in Patients with Allergic Conjunctivitis.
Marini MC, Berra ML, Girado F, et al. · Clin Ophthalmol 2023 · Case Reports, Clinical Trial
- Comparative study on the efficacy and safety of bepotastine besilate versus levocetirizine in chronic spontaneous urticaria: A randomised, open-label, parallel study.
Gayathri E, Sowmya P, Punnagai K, et al. · Indian J Dermatol Venereol Leprol 2023 · Randomized Controlled Trial
- Pharmacokinetic comparisons of bepotastine besilate and bepotastine salicylate in healthy subjects.
Kim KA, Park JY · Clin Drug Investig 2013 · Comparative Study, Randomized Controlled Trial
- Multicenter clinical evaluation of bepotastine besilate ophthalmic solutions 1.0% and 1.5% to treat allergic conjunctivitis.
Macejko TT, Bergmann MT, Williams JI, et al. · Am J Ophthalmol 2010 · Clinical Trial, Phase III, Multicenter Study
- Efficacy of bepotastine besilate ophthalmic solution 1.5% for seasonal allergic conjunctivitis: a randomized, placebo-controlled, natural exposure, clinical trial.
Carr WW, Nayak AS, Ratner PH, et al. · Allergy Asthma Proc 2013 · Multicenter Study, Randomized Controlled Trial
Sponsor: Bausch and Lomb INC
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.